Clinical trial • Phase I • Oncology
Clinical trial in HER2-positive tumors
Phase I trial for HER2-positive tumors. None/Not specified-controlled. 28 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- HER2-positive tumors
- Trial Stage
- Phase I
- Drug Modality
- Diagnostic agent
Key dates
- Initial CTIS Submission Date
- 06-05-2025
- First CTIS Authorization Date
- 07-08-2025
Trial design
None/Not specified-controlled Phase I trial in Netherlands.
- Comparator
- None/Not specified
- Target Sample Size
- 28
Recruitment
- Planned Sample Size
- 28
- Recruitment Window Months
- 16
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 28
Netherlands
- Earliest CTIS Part Ii Submission Date
- 24-07-2025
- Latest Decision Or Authorization Date
- 25-03-2026
- Processing Time Days
- 244
- Number Of Sites
- 1
- Number Of Participants
- 28
Sites
- Site Name
- Radboud universitair medisch centrum Stichting
- Department Name
- Medical Imaging, Nuclear Medicine
- Principal Investigator Name
- James Nagarajah
- Principal Investigator Email
- james.nagarajah@radboudumc.nl
- Contact Person Name
- James Nagarajah
- Contact Person Email
- james.nagarajah@radboudumc.nl
- Number Of Participants
- 28
Sponsor
Primary sponsor
- Full Name
- Radboud universitair medisch centrum Stichting
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)